1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

US FDA panel: Let anti-NGF studies move forward, despite 'severe' joint risks

 
• By Donna Young

After hearing pleas from patients and experts that the available therapies to treat severe pain are inadequate, advisers to the US FDA said they were not ready to slam the door on an experimental class of drugs, known as anti-nerve growth factors (anti-NGFs), which have been linked to serious adverse effects, including bone and joint deterioration leading to joint-replacement surgery.

After hearing pleas from patients and experts that the available therapies to treat severe pain are inadequate, advisers to the US FDA said they were not ready to slam the door on an experimental class of drugs, known as anti-nerve growth factors (anti-NGFs), which have been linked to serious adverse effects, including bone and joint deterioration leading to joint-replacement surgery.

At a 12 March hearing, the FDA's Arthritis Drugs Committee unanimously recommended that, based on the risk-benefit profile for anti-NGFs,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

More from Therapeutic Category

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.